Mer­ck dou­bles down on Sky­hawk's tech to drug RNA, promis­ing $600M per au­toim­mune, meta­bol­ic tar­get

Ear­ly col­lab­o­ra­tions with big-name part­ners lent Sky­hawk Ther­a­peu­tics both the en­dorse­ments and the cap­i­tal to pur­sue a small mol­e­cule plat­form for drug­ging RNA. And they soon want­ed more. When Mer­ck signed on to dis­cov­er can­di­dates against neu­rode­gen­er­a­tion and can­cer last Ju­ly, Bio­gen was just ex­pand­ing the list of neu­ro tar­gets they want to go af­ter.

Now Mer­ck is com­ing back for its own round two, adding au­toim­mune and meta­bol­ic dis­eases to the menu.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN